Educational Interviews

Educational interviews are at the centre of the PCR experience. Whether it’s an expert opinion on a new technique and tool or any of the key topics that interest you, you can find it here. Available online during and after every course, we spotlight the latest procedures, devices, tools and techniques on TAVI, stents and scaffolds, below the knee, LAA closure, STEMI, chronic heart failure, mitral valve replacement and repair and other topics.

Filter By

163 results

Surgical and transcatheter treatment options for tricuspid regurgitation

18 May 2017

The tricuspid valve - is it still the “forgotten valve” it once was? Surgical solutions are available and interventional alternatives are starting to evolve, but are the large number of patients suffering from tricuspid disease and tricuspid regurgitation getting treated? What are the unmet need? Learn more in this fascinating discussion with D. Mylotte, N. Piazza  and S. Bolling as they review the procedures and devices available today and being developed for tomorrow, and why education is so crucial

BIO-RESORT silent diabetes substudy

From EUROPCR 2017

Why invite patients who were not known to have diabetes to undergo an oral glucose tolerance test and an assessment of HbA1c? C. Von Birgelen discusses this intriguing observational substudy of a trial that followed more than 3,500 patients, looking at the critical issue of diabetes, pre-diabetics…and the challenge of silent diabetic patients undergoing PCI with DES. Discover the surprising results and outcomes for each of these groups of patients. What is the critical take-home message and where does this lead our future treatment options? Watch now…

The DISRUPT CAD study Lithoplasty

From EUROPCR 2017

Additional tools for effectively treating heavily calcified arteries remains a challenging and somewhat unmet need. Join T. Brinton as he introduces a trial testing a new technology, lithoplasty, and learn why a balloon-based system offering localized lithotripsy, can effectively disrupt – crack and fracture calcium prior to low pressure dilatation. How was this trial designed, what patients were included and, finally, what were the results in terms of the primary endpoint of safety or of efficacy? Learn more here…

MERES: BRS today…learn what makes each device unique

Bioresorbable vascular scaffolds are a hot topic…but can you distinguish between the different devices being explored today? Join A. Seth as he introduces the unique features of one of the new generation of BRS, the MeRes. With a specific, thin-strut design, we look at major cardiac events in the more than 100 patients now treated, as well as learning about stent thrombosis, safety and efficacy for this novel device… Watch now….

SAVR or TAVI for a patient at high risk for stroke?

Stroke is one of the “devastating” consequences of valve replacement. Join A. P. Kappetein as he reviews what we know today from the first randomised trial to include a complete and detailed neurological exam before intervention. How did TAVI using a self-expanding bioprostheses compare to SAVR in term of treating patients at high-risk for stroke? Learn more here…


From EUROPCR 2017

What is the best strategy for intervention in patients with STEMI or multivessel disease? Should we plan a complete FFR-guided revascularisation or only treat the infarct-related artery? Join E. Omerovic as he reports on further results from this multicentre European and Asian trial and learn why he believes that the FFR-approach is not only good for the patient…but for health system as well in terms of the overall cost for society. Watch now…

AIDA: BRS: still unanswered questions...

From EUROPCR 2017

Where are we going today with BRS and DES? J. Wykrykowska leads us through two-year results of this all-comer trial comparing ABSORB BRS with metallic DES on a one-to-one ratio. With 1,800 patients, learn why reporting of 2-year data was warranted due to safety concerns. Discover when scaffold thrombosis was seen to increase and whether any relevant predictors for scaffold thrombosis were observed. What still needs to be explored in this emerging technology? Enter the discussion here…


From EUROPCR 2017

An interview of Robbert DE WINTER, the Netherlands.

EuroCTO: What is the best option for treating CTO: PCI or optimal medical therapy?

From EUROPCR 2017

Which approach best improves clinical symptoms? Join G. Werner as he reviews this randomized trial whose goal was the assessment of these two strategies and their impact on the overall health of patients at 12 months. Learn of the specificities of this trial including how patients with multivessel disease were included in both arms, as well as the efficacy of either treatment or the number of crossovers after intention-to-treat was decided upon. Finally, which approach proved to be more successful in improving angina frequency or quality of life? Learn more here.

ABSORB Japan: bioresorbable vascular scaffold vs metallic DES in de novo coronary artery lesion

From EUROPCR 2017

What was the nature of the trial designed for BRS approval in Japan? Join K. Kozuma as he underlines the concerns in the use of this “new technology” and discusses current data. Learn why these latest results are positive in terms of safety and efficacy, even in light of the 2-year results which showed higher levels of very late stent thrombosis. Could vessel size play a role? Is a conclusion of non-inferiority with XIENCE near? Understand where we stand today and why by watching now…